AKT Inhibition in Prostate Cancer — Proceedings from a Session Held Adjunct to the 2026 ASCO Genitourinary Cancers Symposium
Oncology Today with Dr Neil Love
00:00
Common Toxicities of AKT Inhibition
Panel discusses diarrhea, hyperglycemia, and rash as expected capivasertib adverse events and management needs.
Play episode from 45:40
Transcript
